Deere (DE) has an average rating of overweight and mean price target of $666.01, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $524.61, Change: $-6.75, Percent Change: -1.27%
(Updates with stock move in headline and first paragraph.)BJ's Wholesale Club shares fell more than 6% in Friday morning trading after fiscal Q1 adjusted earnings declined year over year, even as revenue rose and results beat analysts' estimates.The company reported fiscal Q1 adjusted earnings earlier Friday of $1.10 per diluted share, down from $1.14 a year earlier. Analysts polled by FactSet expected $1.03.Revenue for the quarter ended May 2 was $5.66 billion, up from $5.15 billion a year earlier. Analysts surveyed by FactSet expected $5.44 billion.For fiscal 2026, the company continues to expect adjusted EPS of $4.40 to $4.60. Analysts polled by FactSet expect $4.51.Price: $87.44, Change: $-7.00, Percent Change: -7.41%
Mastercard Asks Brazil's Payment Processors to Help Pay for Banco Master Failure, Bloomberg Reports
Agios Pharmaceuticals (AGIO) said Friday the European Commission granted marketing authorization for Pyrukynd to treat adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.The oral therapy received orphan medicinal product designation in the European Union.The approval was based on results from the two phase 3 clinical trials evaluating the medicine in adults with thalassemia, Agios said.The company added that its partner, Avanzanite Bioscience, will continue to commercialize and distribute Pyrukynd across Europe.Price: $28.58, Change: $-0.21, Percent Change: -0.73%